Graybug Vision, Inc. (GRAY)
Graybug Vision, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Redwood City, CA, US. The stock last traded at $5.50, down 10.80% on the session, giving a market capitalisation of $121.0M. On trailing twelve-month figures it carries a trailing P/E of -4.07, a net margin of 0.0%. Its beta of 1.20 implies it has historically moved more than the broad market.
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Graybug Vision, Inc. is most often compared with the following Healthcare names: